Thiopurine methyltransferase activity in children with acute myeloid leukemia

Sobiak,Joanna; Skalska‑Sadowska,Jolanta; Chrzanowska,Maria; Resztak,Matylda; Kołtan,Sylwia; Wysocki,Mariusz; Wachowiak,Jacek

doi:10.3892/ol.2018.9191

Thiopurine methyltransferase activity in children with acute myeloid leukemia

Authors:
- Joanna Sobiak
- Jolanta Skalska‑Sadowska
- Maria Chrzanowska
- Matylda Resztak
- Sylwia Kołtan
- Mariusz Wysocki
- Jacek Wachowiak
View Affiliations

Affiliations: Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60‑781 Poznań, Poland, Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60‑572 Poznań, Poland, Department of Pediatrics, Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, 85‑094 Bydgoszcz, Poland
Published online on: July 23, 2018 https://doi.org/10.3892/ol.2018.9191
Pages: 4699-4706

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activity of the enzyme thiopurine methyltransferase (TPMT) determines the anti‑leukemic effect of thiopurines used in the chemotherapy of acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). TPMT status and its effects on treatment outcome have been studied extensively in ALL and autoimmune disorders, but few data is available on TPMT in AML. The present study assessed the genetic polymorphisms and activity of TPMT in children with AML at different treatment stages, and compared the results with those obtained for children with ALL. The study included 33 children with AML (0.7‑19.7 years) treated with 6‑thioguanine (6‑TG) according to the AML‑BFM 2004 Protocol. Blood samples were collected at diagnosis, during and following maintenance chemotherapy from 8, 10 and 17 patients with AML (the assay was performed at two time points in 2 patients), respectively. Blood samples from 105 children with ALL were obtained at diagnosis, during the maintenance chemotherapy and following the cessation of the chemotherapy from 16, 55 and 34 children, respectively. The activity of TPMT in red blood cells lysates was measured using an enzymatic reaction based on the conversion of 6‑mercaptopurine into 6‑methylmercaptopurine, involving S‑adenozyl‑L‑methionine as the methyl group donor. TPMT mutations were determined using a polymerase chain reaction/restriction fragment length polymorphism method. Median TPMT activity at diagnosis, during maintenance chemotherapy and following chemotherapy was 43.1, 47,3 and 41.7 nmol 6‑mMP g‑1 Hb h‑1, respectively. All patients with AML exhibited the homozygous TPMT*1/*1 genotype, with the exception of 1, who was a heterozygote with the TPMT*1/*3C genotype and demonstrated a TPMT activity level at diagnosis of 42.5 nmol 6‑mMP g‑1 Hb h‑1. At each chemotherapy stage, the median TPMT activities in children with AML were significantly increased compared with the median TPMT activities in children with ALL. The preliminary results suggest that the TPMT activity in AML may be increased compared with that in ALL. Comprehensive studies on the association between thiopurine metabolism and treatment outcome in AML are required, with regard to the cytogenetic and molecular factors currently used for AML risk stratification.

View Figures

View References

1	de Rooij JD, Zwaan CM and van den Heuvel-Eibrink M: Pediatric AML: From biology to clinical management. J Clin Med. 4:127–149. 2015. View Article : Google Scholar : PubMed/NCBI
2	Tarlock K and Meshinchi S: Pediatric acute myeloid leukemia: Biology and therapeutic implications of genomic variants. Pediatr Clin North Am. 62:75–93. 2015. View Article : Google Scholar : PubMed/NCBI
3	Stensman LM, Kjeldsen E, Nersting J, Schmiegelow K and Hasle H: Treatment-related myelodysplastic syndrome in a child with acute myeloid leukemia and TPMT heterozygosity. J Pediatr Hematol Oncol. 37:e242–e244. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pui CH, Carroll WL, Meshinchi S and Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
5	Mussai FJ, Yap C, Mitchell C and Kearns P: Challenges of clinical trial design for targeted agents against pediatric leukemias. Front Oncol. 4:3742015. View Article : Google Scholar : PubMed/NCBI
6	Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, et al: Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from study AML-BFM 2004. Blood. 122:37–43. 2013. View Article : Google Scholar : PubMed/NCBI
7	Munshi PN, Lubin M and Bertino JR: 6-thioguanine: A drug with unrealized potential for cancer therapy. Oncologist. 19:760–765. 2014. View Article : Google Scholar : PubMed/NCBI
8	Pizzo PA and Poplack DG: Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams and Wilkins; pp. 3092011
9	Coulthard S and Hogarth L: The thiopurines: An update. Invest New Drugs. 23:523–532. 2005. View Article : Google Scholar : PubMed/NCBI
10	Coulthard SA, Howell C, Robson J and Hall AG: The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood. 92:2856–2862. 1998.PubMed/NCBI
11	Katara P and Kuntal H: TPMT polymorphism: When shield becomes weakness. Interdiscip Sci. 8:150–155. 2016. View Article : Google Scholar : PubMed/NCBI
12	Lennard L and Lilleyman JS: Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit. 18:328–334. 1996. View Article : Google Scholar : PubMed/NCBI
13	Abaji R and Krajinovic M: Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: Influence on treatment response. Pharmgenomics Pers Med. 10:143–156. 2017.PubMed/NCBI
14	Schmiegelow K, Forestier E, Kristinsson J, Söderhäll S, Vettenranta K, Weinshilboum R and Wesenberg F: Nordic Society of Paediatric Haematology and Oncology: Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Leukemia. 23:557–564. 2009. View Article : Google Scholar : PubMed/NCBI
15	Lennard L, Cartwright CS, Wade R and Vora A: Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003. Br J Haematol. 170:550–558. 2015. View Article : Google Scholar : PubMed/NCBI
16	Tamm R, Mägi R, Tremmel R, Winter S, Mihailov E, Smid A, Möricke A, Klein K, Schrappe M, Stanulla M, et al: Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies. Clin Pharmacol Ther. 101:684–695. 2017. View Article : Google Scholar : PubMed/NCBI
17	Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D, Jazbec J, et al: Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 32:174–184. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chrzanowska M, Kuehn M, Januszkiewicz-Lewandowska D, Kurzawski M and Droździk M: Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia. Acta Pol Pharm. 69:405–410. 2012.PubMed/NCBI
19	Kröplin T, Weyer N, Gutsche S and Iven H: Thiopurine S-methyltransferase activity in human erytrocytes: A new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol. 54:265–271. 1998. View Article : Google Scholar : PubMed/NCBI
20	Kröplin T and Iven H: Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 donors. Eur J Clin Pharmacol. 56:343–345. 2000. View Article : Google Scholar : PubMed/NCBI
21	Kurzawski M, Gawrońska-Szklarz B and Droździk M: Frequency distribution of thiopurine S-methyltransferase alleles in a polish population. Ther Drug Monit. 26:541–545. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kotur N, Dokmanovic L, Janic D, Stankovic B, Krstovski N, Tosic N, Katsila T, Patrinos GP, Zukic B and Pavlovic S: TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. Pharmacogenomics. 16:1701–1712. 2015. View Article : Google Scholar : PubMed/NCBI
23	Chouchana L, Narjoz C, Roche D, Golmard JL, Pineau B, Chatellier G, Beaune P and Loriot MA: Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics. 15:745–757. 2014. View Article : Google Scholar : PubMed/NCBI
24	Anasari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, Meenan J, Yim A and Sanderson J: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 16:1743–1750. 2002. View Article : Google Scholar : PubMed/NCBI
25	Chouchana L, Narjoz C, Beaune P, Loriot MA and Roblin X: Review article: The benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 35:15–36. 2012. View Article : Google Scholar : PubMed/NCBI
26	Karas-Kuzelicki N and Mlinaric-Rascan I: Individualization of thiopurine therapy: Thiopurine S-methyltransferase and beyond. Pharmacogenomics. 10:1309–1322. 2009. View Article : Google Scholar : PubMed/NCBI
27	Roberts RL, Gearry RB, Bland MV, Sies CW, George PM, Burt M, Marinaki AM, Arenas M, Barclay ML and Kennedy MA: Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics. 18:434–438. 2008. View Article : Google Scholar : PubMed/NCBI
28	Chouchana L, Roche D, Jian R, Beaune P and Loriot MA: Poor response to thiopurine in inflammatory bowel disease: How to overcome therapeutic resistance? Clin Chem. 59:1023–1026. 2013. View Article : Google Scholar : PubMed/NCBI
29	Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M, Franca R, Rabusin M, Valsecchi MG, Pei D, et al: PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 21:4793–4804. 2012. View Article : Google Scholar : PubMed/NCBI
30	Smid A, Karas-Kuzelicki N, Jazbec J and Mlinaric-Rascan I: PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 6:302442016. View Article : Google Scholar : PubMed/NCBI
31	Karas-Kuželički N, Šmid A, Tamm R, Metspalu A and Mlinarič-Raščan I: From pharmacogenetics to pharmacometabolomics: SAM modulates TPMT activity. Pharmacogenomics. 15:1437–1449. 2014. View Article : Google Scholar : PubMed/NCBI
32	Milek M, Kuzelicki Karas N, Smid A and Mlinaric-Rascan I: S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts. Biochem Pharmacol. 77:1845–1853. 2009. View Article : Google Scholar : PubMed/NCBI
33	Lennard L, Cartwright CS, Wade R, Richards SM and Vora A: Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol. 76:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
34	Chouchana L, Fernández-Ramos AA, Dumont F, Marchetti C, Ceballos-Picot I, Beaune P, Gurwitz D and Loriot MA: Molecular insight into thiopurine resistance: Transcriptomic signature in lymphoblastoid cell lines. Genome Med. 7:372015. View Article : Google Scholar : PubMed/NCBI
35	Gibson B, Perentesis J, Alonzo TA and Kaspers GL: Treatment of Acute Myeloid LeukemiaChildhood Leukemia. Springer-Verlag; Berlin Heidelberg: pp. 136–137. 2011
36	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000018-39/DE(entry date 20 April 2018.).
37	Asadov C, Aliyeva G and Mustafayeva K: Thiopurine S-methyltransferase as a pharmacogenetic biomarker: Significance of testing and review of major methods. Cardiovasc Hematol Agents Med Chem. 15:23–30. 2017. View Article : Google Scholar : PubMed/NCBI